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OBJECTIVE
This study explored neoplasm risk with liraglutide versus placebo in the LEADER
(Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome
Results) cohort.
RESEARCH DESIGN AND METHODS
LEADER (NCT01179048) was an international, phase 3b, randomized, double-blind,
controlled trial. Participants aged ‡50 years with type 2 diabetes and high car-
diovascular risk were assigned 1:1 to receive liraglutide (£1.8 mg daily; n = 4,668)
or placebo (n = 4,672) in addition to standard care and monitored for 3.5–5 years
(median follow-up 3.8 years). The occurrence of neoplasms was a prespecified,
exploratory secondaryendpoint.Posthocanalysesof the timeto thefirst confirmed
neoplasms were conducted using a Cox regression model.
RESULTS
Neoplasm was confirmed in 10.1% of patients with liraglutide versus 9.0% with
placebo (hazard ratio [HR] 1.12 [95% CI 0.99; 1.28]). The HR (95% CI) for liraglutide
versus placebo was 1.06 (0.90; 1.25) for malignant neoplasms and 1.16 (0.93; 1.44)
for benign neoplasms. Sensitivity analyses excluding neoplasms occurring <1 year
or <2 years after randomization and analyses by sex provided similar results.
In our main analyses, the 95% CI for the HR included one for all malignant neo-
plasms evaluated (including pancreatic and thyroid neoplasms) except for prostate
neoplasms, which occurred in fewer liraglutide-treated patients.
CONCLUSIONS
LEADERwas not primarily designed to assess neoplasm risk. Firm conclusions cannot
be made regarding numeric imbalances observed for individual neoplasm types
(e.g., pancreatic cancer) that occurred infrequently. LEADER data do, however, ex-
clude a major increase in the risk of total malignant neoplasms with liraglutide
versus placebo. Additional studies are needed to assess longer-term exposure.
Diabetes and obesity have been identified as risk factors for cancer and cancer-related
mortality (1–5). Glucose-lowering medications may also affect the risk of these events
(1,3). Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) improve glycemic
control with a low risk of hypoglycemia in people with type 2 diabetes (6). GLP-1
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receptor expression has been reported
in a wide range of rodent and human
tissues, including the pancreatic islets,
lung, heart, kidney, gastrointestinal tract,
pituitary, skin, and several regions of the
nervous system (7,8). This widespread
expression of the GLP-1 receptor may
help to explain the range of effects of
GLP-1RAs (9–15).
Data from some preclinical (16–19),
clinical (15), and/or epidemiological da-
tabase studies (20,21) have suggested
an increase in the risk of thyroid cancer
(16,20,21), pancreatic cancer (17,18,20,
21), intestinal neoplasms (15,19), and
breast neoplasms (15) with the use of
incretin-based therapy (GLP-1RAs and/or
dipeptidyl peptidase 4 [DPP-4] inhibitors).
In contrast, other clinical and epidemio-
logical database studies have indicated
that incretin-based therapy does not in-
crease the risk of these events (22–25).
Results from large, prospective clinical
trials may help clarify a potential risk
for neoplasms with GLP-1RAs or other
glucose-lowering medications (26).
The LEADER (Liraglutide Effect and
Action in Diabetes: Evaluation of Cardio-
vascular Outcome Results) trial was de-
signed to assess the cardiovascular (CV)
safety of liraglutide but provided the
opportunity to evaluate other impor-
tant safety end points in a population
of 9,340 participants monitored for
3.5–5 years (median follow-up, 3.8)
(11). The primary analysis showed
liraglutide treatment was associated
with a lower rate of major adverse CV
events and total mortality (11). The pres-
ent report explores intermediate-term
neoplasm risk with liraglutide versus
placebo, based on detailed analyses of
data from LEADER.
RESEARCH DESIGN AND METHODS
Trial Design
The design of the LEADER trial (clinicaltrials
.gov, NCT01179048) has been published
previously (11,27). LEADER was a phase
3b, randomized, double-blind, controlled
trial, conducted between 2010 and
2015 in 32 countries (11,27). During the
trial, 9,340 participants aged $50 years
with type 2 diabetes and high CV risk
were assigned, in a 1:1 ratio, to receive
liraglutide (up to 1.8 mg daily) or
matched placebo as a subcutaneous
injection, in addition to their standard-
of-care treatment (11,27). The pres-
ence of malignant neoplasms requiring
chemotherapy, surgery, radiotherapy,
or palliative therapy in the previous
5 years was an exclusion criterion. Also
excluded were patients with a familial or
personal history of multiple endocrine
neoplasia type 2 or medullary thyroid
cancer (MTC) (11). Patients with intra-
epithelial squamous cell carcinoma
of the skin (Bowen’s disease) treated
with topical 5-fluorouracil and patients
with basal cell skin cancer were al-
lowed to enter the trial (11). Partici-
pants were monitored for 3.5–5 years
(median follow-up, 3.8) (11). The pri-
mary end point was time to first occur-
rence of CV death, nonfatal (including
silent) myocardial infarction, or nonfatal
stroke (11).
Evaluation of Neoplasms
The occurrence of neoplasms was a pre-
specified, exploratory secondary end
point. The investigators were asked to
report all types of suspected neoplasms,
including malignant neoplasm, in situ
neoplasm, and neoplasm of uncertain
or unknown behavior.
Potential neoplasms identified via in-
vestigator reports,MedicalDictionary for
Regulatory Activities (MedDRA) search,
the event adjudication committee (EAC),
or the contract research organization
were sent for adjudication (Supplemen-
tary Fig. 1). All potential neoplasms were
adjudicated in a blinded manner by the
neoplasms subcommittee of the exter-
nal, independent EAC. The clinical eval-
uation of neoplasms by the EAC could be
based on diagnostic tests, pathology
reports, specialist consultations, related
imaging reports, and/or biomarkers. For
thyroid neoplasms, operative reports
and relevant laboratory findings (e.g.,
tumor markers) were also used as di-
agnostic criteria. The EAC used a prespe-
cified definition for adjudication of
potential neoplasms, and a pathologic
diagnosis by histology or cytology was
considered of foremost importance for
confirmation. After database lock, EAC-
confirmed neoplasm events categorized
as tissue of origin “other”were classified
according to the organ system affected
by medically qualified personnel at Novo
Nordisk.
The EACwas not required to specify its
reason for not confirming a neoplasm
event. Possible reasons for nonconfir-
mation could include sufficient evidence
that an event was not a neoplasm or
insufficient evidence (e.g., lack of a pa-
thology report) to confirm an event as a
neoplasm.
To confirm the robustness of the anal-
yses based on adjudicated data, a review
of investigator-reported adverse events
of malignant neoplasms was also under-
taken by the sponsor, who performed
MedDRA term searches after the un-
blinding of data after database lock. In
addition, case reviews of all investigator-
reported adverse events of malignant
neoplasms not confirmed by the EAC
were performed by the sponsor at this
time. Because the EAC was blinded,
external, and independent, its assess-
ments were prioritized over the spon-
sor’s assessments; however, the latter
are reported for transparency and com-
pleteness.
Evaluation of Cause of Death
All deaths were adjudicated by a CV
subcommittee to identify potential CV
deaths. The subcommittee classified
the cause of deaths as “known” or “un-
known” and further, for a known cause,
as CV or non-CV deaths. This required
formal agreement/adjudication. Based
on comments that were not subject to
reconciliation between adjudicators, the
sponsor further categorized the non-CV
deaths according to plausible cause, which
could include neoplastic disease.
Statistical Methods
Post hoc analyses of the time to the first
EAC-confirmed neoplasm events were
conducted using a Cox regression model
to compare liraglutide treatment with
placebo. Exploratory statistical testing
without correction for multiplicity was
performed if one or more events oc-
curred in both treatment groups. The
main analyses used an intention-to-
treat approach, including all first events
collected from randomization until the
end-of-trial follow-up visit.
Plots were prepared showing the cu-
mulative incidence probability of con-
firmed neoplasm index events with
liraglutide or placebo over time. The
cumulative incidence was estimated
using the Aalen-Johansen method with
death as a competing risk. Definitions
of neoplasm index events, first events,
and recurrent events are provided in the
Supplementary Data.
Sensitivity analyses were conducted
that excludedneoplasmevents occurring
,1 year and ,2 years after randomi-
zation to treatment, in case of an induc-
tion or latency time of these durations.
In addition to Cox regression, a Fine and
Gray method that adjusted for death
as a competing risk was also used to
analyze the time to the first neoplasm
events.
Separate summaries were prepared
to investigate the occurrence of neo-
plasms in sex (male and female) and age
(,65 and$65 years) subgroups. A Cox
regression model was used to conduct
post hoc analyses to assess the inter-
action between treatment group and
these subgroups. AP valueof,0.05was
taken to indicate a statistically signifi-
cant difference. However, because the
interaction analyses were exploratory,
the results of these analyses should be
interpreted with caution.
In this report, increased attention is
paid to specific types of neoplasms, in-
cluding pancreatic, thyroid, colorectal,
breast, prostate, nonmelanoma skin,
melanoma, and lung and bronchus neo-
plasms. This selection of neoplasms of
interest was based on several consider-
ations, including GLP-1 receptor tissue ex-
pression (7,8), published findings from
LEADER (11), and other previously re-
ported data. The sponsor also conducted
a post hoc review of clinical narratives
to categorize confirmed malignant neo-
plasms of the liver and gallbladder
or bile duct. The investigator-reported




The baseline characteristics for the LEADER
trial population (n = 9,340) have been
published previously (11). The mean du-
ration of diabetes (mean glycated hemo-
globin [HbA1c] 8.7% [72 mmol/mol]) was
12.8 years, and 81.3%of theparticipants
had established CV disease (11). Partic-
ipants were a mean age of 64.3 years,
and 64.3%weremen. At baseline, 12.1%
of participants were smokers, 46.5%were
previous smokers, and 41.4% had never
smoked.
Exposure to Randomized Treatment
and Follow-up
As reported previously, the median du-
ration of exposure to liraglutide or pla-
cebo was 3.5 years (11). The median
dose of liraglutide was 1.78 mg daily
(interquartile range1.54–1.79), including
periods during which the participants
did not receive liraglutide (11). Overall,
96.8% of all randomized participants
completed a final visit, died, or expe-
rienced a component of the primary
composite outcome, and 99.7% of the
participants had known vital status at
the end of the trial (11).
Adjudication Flow for Neoplasms
According to the broad study definition,
3,802 potential neoplasms were identi-
fied and sent for adjudication. The EAC
confirmed 1,477 (38.8%) of the potential
neoplasms sent for adjudication as neo-
plasms (Supplementary Fig. 1).
Frequency of Confirmed Neoplasms
Excluding duplicate events and events
occurring before randomization or after
the end-of-trial follow-up, 1,123 con-
firmed neoplasms occurred. A total of
595 neoplasms (in 470 of 4,668 patients)
in the liraglutide group and 528 neo-
plasms (in 419 of 4,672 patients) in the
placebo group were confirmed. Overall,
the proportion of patients who had
confirmed neoplasms was 10.1% (3.34
events per 100 patient-years of obser-
vation [PYO]) in the liraglutide group and
9.0% in the placebo group (2.98 events
per 100 PYO; estimated hazard ratio [HR]
1.12 [95% CI 0.99; 1.28]) (Fig. 1A). The
proportion of patients with confirmed
malignant neoplasms was 6.2% (1.92
events per 100 PYO), and a benign neo-
plasm was confirmed in 3.4% of patients
(1.03 events per 100 PYO). The HR (95%
CI) for liraglutide versus placebo was
1.06 (0.90; 1.25) for “all malignant neo-
plasms” and 1.16 (0.93; 1.44) for “all
benign neoplasms” (Fig. 1A).
The cumulative incidence of confirmed
overall neoplasms, malignant neoplasms,
and benign neoplasms was similar with
liraglutide treatment and placebo during
the randomized treatment period (Fig. 2).
A small separation in the cumulative in-
cidence of confirmed benign neoplasms
appeared after;14 months (Fig. 2G) and
was also observed for the cumulative
incidence of confirmed overall neoplasms
(Fig. 2A), but thereafter and for the re-
mainder of the trial these events occurred
at constant and similar rates in both
treatment groups.
Sensitivity Analyses
Sensitivity analyses excluding neoplasms
occurring,1 year (Figs. 1B and 2B, E, and
H) or ,2 years after randomization to
treatment (Figs. 1C and 2C, F, and I)
provided similar results to the main
analysis for the overall neoplasm cate-
gories evaluated (“all neoplasms,” “all
malignant neoplasms,” and/or “all be-
nign neoplasms”). The subdistribution
HRs estimated using the Fine and Gray
method were consistent with the Cox
regression analyses.
Results from the sensitivity analyses of
events captured by the sponsor’s MedDRA
searches for malignant tumors were gen-
erally consistent with the adjudicated
outcome (Supplementary Table 1). Addi-
tional data regarding pancreatic cancer
are provided in Supplementary Table 2.
FrequencyofConfirmedNeoplasmsby
Sex and Age Subgroups
The proportions of patients experiencing
confirmed overall neoplasms, malignant
neoplasms, or benign neoplasms with
liraglutide versus placebo were similar with-
in male and female subgroups (Table 1).
The frequencies of overall neoplasms
(HR 1.24 [95% CI 1.04; 1.47]; P = 0.10
for interaction) as well as combined
malignant neoplasms (HR 1.15 [95% CI
0.94; 1.41]; P = 0.24 for interaction) and
combined benign neoplasms (HR 1.21
[95% CI 0.89; 1.64]; P = 0.72 for inter-
action) were numerically higher with
liraglutide versus placebo in the sub-
group aged $65 years (Table 1).
Deaths Among Individuals With
Malignant Neoplasm
Among patients who had a confirmed
malignant neoplasm, the proportions
that died of any cause (including deaths
not related to cancer) were similar in the
liraglutide and placebo groups (25.3% vs.
25.1%, respectively) (Table 2). In both
treatment groups, most of these deaths
were classified as non-CV and attributed
to malignancy (19.6% vs. 19.7% of pa-
tients with an EAC-confirmed malignant
neoplasm treated with liraglutide vs.
placebo, respectively) (Table 2).
Neoplasms of Interest
Results for pancreatic, thyroid, colorec-
tal, breast, prostate, nonmelanoma skin,
melanoma, and lung and bronchus neo-
plasms are presented in Fig. 1, Table 2,
and the Supplementary Data. Findings
from the analyses of malignant hepatic
and biliary neoplasms are presented in
the Supplementary Data. Demographics
and baseline characteristics of patients
Figure 1—Frequency of all confirmedneoplasms,malignant neoplasms, benign neoplasms, and neoplasms of interest.A:Main analysis.B and C: Events
occurring later than 1 year (B) and later than 2 years (C) after randomization (sensitivity analysis) (11). Data presented in this table refer to the full
analysis set (FAS). HRs are derived from a Cox proportional hazard regression model adjusted for treatment. Firth correction was used for malignant
pancreatic neoplasms occurring later than 2 years after randomization (C). Proportions for breast neoplasms are calculated based on the number of
female participants. Proportions for prostate neoplasms are calculated based on the number of male participants. Reprinted from Marso et al. (11)
with permission from the Massachusetts Medical Society. © 2016 Massachusetts Medical Society.
who experienced a malignant neoplasm
of interest are presented in Supplemen-
tary Table 3.
The most frequently occurring type of
confirmed malignant neoplasm in the
overall study population was malignant
nonmelanoma skin neoplasm (1.5% of
patients [n = 140]). In the main analyses
comparing the occurrence of confirmed
neoplasms with liraglutide treatment
versus placebo, the 95% CI for the HR
included one for all neoplasms of interest
evaluated, except for malignant prostate
neoplasms, which were experienced by a
lower proportion of patients receiving
liraglutide (HR 0.54 [95% CI 0.34; 0.88])
(Fig. 1A).Malignant pancreatic neoplasm
or malignant melanoma events were
confirmed infrequently in both groups
and for more patients in the liraglutide
group (n = 13 [0.28%] for each type of
neoplasm) than in the placebo group
(n = 5 [0.11%] for each type of neoplasm
[HR 2.59 (95% CI 0.92; 7.27)] in the main
analysis) (Fig. 1A). No patients in the
placebo group had a confirmed malig-
nant pancreatic neoplasmafter 2 years of
randomized treatment compared with
five patients (0.11%) in the liraglutide
group (HR 10.90 [95% CI 0.46; 260.03]),
and only one patient (0.02%) had a con-
firmed malignant melanoma after 1 year
of receiving placebo compared with
Figure 2—Cumulative incidence plots for confirmed neoplasms. A: Confirmed neoplasm index events. B and C: Confirmed neoplasm index events
occurring later than 1 year (B) and later than 2 years (C) after randomization (sensitivity analysis).D: Confirmedmalignant neoplasm index events. E and
F: Confirmed malignant neoplasm index events occurring later than 1 year (E) and later than 2 years (F) after randomization (sensitivity analysis). G:
Confirmed benign neoplasm index events. H and I: Confirmed benign neoplasm index events occurring later than 1 year (H) and later than 2 years (I)
after randomization (sensitivity analysis). Cumulative incidence was estimated using the Aalen-Johansen method with death as a competing risk.
A cumulative incidence probability of 0.1 is equivalent to 10%. HRs are derived from a Cox proportional hazard regression model adjusted for
treatment and are for the proportion of patients with an event with liraglutide vs. placebo.
11 patients (0.24%) in the liraglutide
group (HR 10.95 [95% CI 1.41; 84.82])
(Fig. 1). Details for individual cases of
malignant or premalignant pancreatic
neoplasm or melanoma are provided in
Supplementary Tables 2 and 4. Several
patients who developedmalignant pan-
creatic neoplasm experienced weight
loss before their diagnosis, and some
experienced increases in HbA1c before
diagnosis, but there was no universal
pattern.
CONCLUSIONS
LEADER has provided information about
intermediate-term neoplasm risk with
liraglutide versus placebo (both in com-
bination with standard care) in 9,340
patients with type 2 diabetes monitored
for 3.5–5 years. There was a greater total
number of neoplasms with liraglutide
compared with placebo (470 vs. 419
total [benign, premalignant, ormalignant]
neoplasms, respectively; HR 1.12 [95%
CI 0.99; 1.28]). However, our overall
analyses do not suggest a major increase
(.25% based on the 95% CI) in the risk
of malignant neoplasms with liraglutide,
in general terms, versus placebo (HR 1.06
[95% CI 0.90; 1.25]).
Overall cancer rates, although of clin-
ical interest, do not have a known bi-
ological relevancebecause all carcinogens
reported to date affect specific cancer
subtypes. In our study we have limited
power to examine any specific cancer
subtype. The primary end point power
calculation for LEADER determined that
611 events were required to exclude an
HR .1.3 with 90% power. The cancer
subtype with the highest number of
events in LEADER was nonmelanoma
skin cancer, affecting 140 patients
(liraglutide, 78 patients [1.7%]; placebo,
62 patients [1.3%]) during the entire
study period. This number of events
gives a power of 34% to exclude an HR
.1.3 for nonmelanoma skin cancer; to
exclude an HR .1.3% with a power of
90%, the number of patients required is
;36,000 (assuming the observed rate of
nonmelanoma skin cancer events of 0.4%
subjects/year and $3.5 years’ observa-
tion time). Beyond these limitations
around the power of the trial to detect
differences in cancer incidence, the lim-
ited time frame (median follow-up of
3.8 years) is inadequate to exclude the
carcinogenic potential of a drug.
The proportion of patients with con-
firmed malignant neoplasms during
LEADER was 6.2% (1.92 events per
100 PYO), which is lower than that for
the primary composite end point for
major adverse CV events (11). To our
knowledge, evidence from global epide-
miological studies on cancer prevalence
in people with type 2 diabetes is lacking.
It is therefore difficult to evaluate how
overall cancer rates in LEADER compare
with those in the general population of
patients with type 2 diabetes. Among
those patients in LEADER with a con-
firmedmalignant neoplasm,most deaths
were due to malignancy. The occurrence
of deaths attributable to malignancy
was similar with liraglutide and placebo;
hence, cause of death seemed to reflect
the prognosis of underlying malignant
disease, irrespective of treatment group.
There was no suggestion of an asso-
ciation between liraglutide exposure
and development of malignant neoplasms
in the liraglutide clinical development
program for treatment of type 2 diabetes
(at doses up to 1.8 mg daily for up to
22 months) (14). Slight imbalances in
rates of papillary thyroid cancer and
prostate cancer were identified with
liraglutide versus a pooled comparator
group consisting of an active compar-
ator and placebo; however, rates were
similar compared with placebo alone
(14).
In LEADER, the frequency of confirmed
malignant thyroid neoplasm was similar
in the liraglutide andplacebo groups, and
the only observed case of MTC occurred
in a patient assigned to placebo. Fewer
participants experienced malignant pros-
tate neoplasms in the liraglutide group
than in the placebo group (11). In vitro
studies have shown that liraglutide and
exenatide significantly inhibit prolifera-
tion in human prostate cancer cell lines
through GLP-1 receptor–dependent mech-
anisms (28,29), giving some plausibility
to our observation. Alternatively, greater
urinary frequency among placebo-treated
patients (due to greater hyperglycemia
andmore diuretic use), and consequen-
tly more frequent investigation, could
account for the small difference.
We report a numeric imbalance in
the frequency of adjudication-confirmed
malignant pancreatic neoplasms in the
liraglutide group versus placebo group
(0.28% [n = 13] vs. 0.11% [n = 5], re-
spectively; HR 2.59 [95% CI 0.92; 7.27]).
Additional details on the capture and
adjudication of these cases can be found
in the Supplementary Data (Neoplasms
of interest: Pancreatic neoplasms). The
development of clinically evident pan-
creatic cancer is a process that takes
many years (30). A substantial number of
our patients with confirmed malignant
pancreatic neoplasms had advanced




n (%) HR (95% CI)





Full analysis set 4,668 (100.0) 4,672 (100.0)
All neoplasms 470 (10.1) 419 (9.0) 1.12 (0.99; 1.28)
Female 127 (7.7) 123 (7.3) 1.04 (0.81; 1.34) Sex: 0.50
Male 343 (11.4) 296 (9.9) 1.16 (0.99; 1.35)
Aged ,65 years 178 (7.1) 177 (7.1) 0.99 (0.80; 1.22) Age: 0.10
Aged $65 years 292 (13.5) 242 (11.1) 1.24 (1.04; 1.47)
All malignant neoplasms 296 (6.3) 279 (6.0) 1.06 (0.90; 1.25)
Female 86 (5.2) 77 (4.6) 1.13 (0.83; 1.54) Sex: 0.60
Male 210 (7.0) 202 (6.8) 1.03 (0.85; 1.25)
Aged ,65 years 101 (4.0) 106 (4.2) 0.94 (0.71; 1.23) Age: 0.24
Aged $65 years 195 (9.0) 173 (8.0) 1.15 (0.94; 1.41)
All benign neoplasms 168 (3.6) 145 (3.1) 1.16 (0.93; 1.44)
Female 41 (2.5) 42 (2.5) 0.98 (0.64; 1.51) Sex: 0.40
Male 127 (4.2) 103 (3.4) 1.22 (0.94; 1.59)
Aged ,65 years 79 (3.1) 70 (2.8) 1.11 (0.80; 1.53) Age: 0.72
Aged $65 years 89 (4.1) 75 (3.5) 1.21 (0.89; 1.64)
Data presented in this table refer to the full analysis set. HRs are derived from a Cox proportional
hazard regression model adjusted for treatment.
stages, suggesting the tumors originated
well before the patients were recruited
into LEADER.
Although earlier studies, subject to
criticism on methodological grounds,
suggested an increased risk for pancre-
atic tumors with incretin-based therapy
(18,20,21), a recent large, international
registry study did not confirm an in-
creased risk of pancreatic cancer versus
sulfonylureas (median follow-up 1.3–2.8
years) (23), in line with a U.S. insur-
ance claims database study that com-
pared liraglutide with non–GLP-1–based
therapy (median follow-up 15 months)
(22). Monitoring of pancreatic cancer in
CV outcome trials (such as LEADER) has
been cited as a strategy for increasing
knowledge in this area (26). To date,
CV outcome trials have consistently
reported pancreatic cancer occurs in
similar or fewer numbers of patients
receiving GLP-1RAs than placebo:
semaglutide (SUSTAIN-6 [Trial to Evalu-
ate Cardiovascular and Other Long-term
Outcomes With Semaglutide in Subjects
With Type 2 Diabetes]), with a mean
observation time of 2.1 years; lixisena-
tide (ELIXA [Evaluation of Lixisenatide in
Acute Coronary Syndrome]), with a me-
dian follow-up of 25 months; and exena-
tide once weekly (EXSCEL [Exenatide
Study of Cardiovascular Event Lower-
ing]), with a median follow-up of 3.2
years (12,31,32). A recent meta-analysis
of all GLP-1RA CV outcome trials (includ-
ing LEADER) also reported an absence of
a significant effect for GLP-1RA on rates
of pancreatic cancer and MTC, albeit
with significant heterogeneity between
the four eligible trials (33).
We also report a numeric imbalance in
the occurrence of adjudication-confirmed
malignant melanoma with liraglutide
(0.28% [n = 13]) vs. placebo (0.11%
[n = 5], HR 2.59 [95% CI 0.92; 7.27]). Only
one patient developed malignant mela-
noma after 1 year of receiving placebo.
The low numbers of patients led to wide
CIs for the HRs for malignant melanoma,
thus precluding firm conclusions. The
HR for skin neoplasms with semaglutide
versus placebo in SUSTAIN-6 was 1.41
(95%CI 0.76; 2.63), though the relevance
of comparison with our analysis is very
limited, with only one of the six skin
neoplasms reported in SUSTAIN-6 being
classified as malignant melanoma (12).
Theprimary reports for ELIXA andEXSCEL
did not include data specific to skin
neoplasms (31,32). A meta-analysis of
randomized clinical trials of 24 weeks’
to 5 years’ duration showed that DPP-4
inhibitors were not associated with a
significantly increased risk of developing
malignant melanoma (25).
Preclinical data suggest that GLP-1RAs
may have GLP-1 receptor-dependent in-
testinotrophic effects (19). Treatment
with exenatide for 4 weeks significantly
increased polyp number and size, pri-
marily in the distal small bowel (19), an
atypical location for human gastrointes-
tinal adenomas.
Table 2—Confirmed deaths, including deaths not related to cancer, among
patients with confirmed malignant neoplasm
Liraglutide Placebo
n (%) n (%)
All malignant neoplasms 296 (100.0) 279 (100.0)
All-cause mortality 75 (25.3) 70 (25.1)
Known cause of death 73 (24.7) 64 (22.9)
CV death 8 (2.7) 1 (0.4)
Non-CV death 65 (22.0) 63 (22.6)
Malignancy 58 (19.6) 55 (19.7)
Malignant pancreatic neoplasms 13 (100.0) 5 (100.0)
All-cause mortality 11 (84.6) 5 (100.0)
Known cause of death 11 (84.6) 5 (100.0)
CV death 0 (0.0) 0 (0.0)
Non-CV death 11 (84.6) 5 (100.0)
Malignancy 11 (84.6) 5 (100.0)
Malignant thyroid neoplasms 5 (100.0) 3 (100.0)
All-cause mortality 0 (0.0) 0 (0.0)
Malignant colorectal neoplasms 28 (100.0) 28 (100.0)
All-cause mortality 6 (21.4) 6 (21.4)
Known cause of death 6 (21.4) 4 (14.3)
CV death 0 (0.0) 0 (0.0)
Non-CV death 6 (21.4) 4 (14.3)
Malignancy 3 (10.7) 4 (14.3)
Malignant breast neoplasms (female only) 21 (100.0) 20 (100.0)
All-cause mortality 1 (4.8) 1 (5.0)
Known cause of death 1 (4.8) 1 (5.0)
CV death 1 (4.8) 0 (0.0)
Non-CV death 0 (0.0) 1 (5.0)
Malignancy 0 (0.0) 1 (5.0)
Malignant prostate neoplasms (male only) 26 (100.0) 47 (100.0)
All-cause mortality 0 (0.0) 6 (12.8)
Known cause of death – 6 (12.8)
CV death 0 (0.0) 0 (0.0)
Non-CV death 0 (0.0) 6 (12.8)
Malignancy 0 (0.0) 3 (6.4)
Malignant nonmelanoma skin neoplasm 78 (100.0) 62 (100.0)
All-cause mortality 3 (3.8) 3 (4.8)
Known cause of death 3 (3.8) 3 (4.8)
CV death 1 (1.3) 0 (0.0)
Non-CV death 2 (2.6) 3 (4.8)
Malignancy 1 (1.3) 1 (1.6)
Malignant melanoma 13 (100.0) 5 (100.0)
All-cause mortality 2 (15.4) 1 (20.0)
Known cause of death 2 (15.4) 0 (0.0)
CV death 0 (0.0) 0 (0.0)
Non-CV death 2 (15.4) 0 (0.0)
Malignancy 2 (15.4) 0 (0.0)
Malignant lung and bronchus neoplasms 28 (100.0) 33 (100.0)
All-cause mortality 21 (75.0) 22 (66.7)
Known cause of death 20 (71.4) 20 (60.6)
CV death 2 (7.1) 0 (0.0)
Non-CV death 18 (64.3) 20 (60.6)
Malignancy 17 (60.7) 20 (60.6)
The EAC CV subcommittee classified deaths with a known cause into CV or non-CV deaths. The
sponsor further categorized the deaths according to plausible cause.
In clinical trials of liraglutide at higher
doses (up to 3.0 mg daily for the weight
management indication), small imbalan-
ces between treatment groups were
noted in the number of patients with
benign colorectal neoplasm events (n =
17 [0.52%] with liraglutide vs. n = 4
[0.22%] with placebo; odds ratio 2.39
[95% CI 0.78; 9.76]) (15). These findings
were not reproduced in LEADER, where
the liraglutide dose was lower (up to
1.8 mg daily).
Furthermore, in clinical trials of liraglutide
for weight management (up to 3.0 mg
daily), an imbalance was reported in the
number of women with malignant or
premalignant breast neoplasms in the
liraglutide (n = 14 [0.59%]) versus placebo
group (n = 3 [0.23%]; odds ratio 2.56 [95%
CI 0.71; 13.91]) (15). It was speculated
that weight loss may have led to en-
hanced detection of breast neoplasms in
liraglutide-treated women (15). Similar
findings were reported from an obser-
vational study in GLP-1RA users (34).
In LEADER, with longer exposure in a
larger population with more cases re-
ported, the overall incidence of con-
firmed malignant breast neoplasms was
similar across the liraglutide and placebo
groups.
Our study has limitations. First,
LEADER was not primarily designed or
powered to provide conclusive data re-
garding occurrence of neoplasms with
liraglutide. A relatively low frequency
of neoplasms was observed for most
tissues, precluding firm conclusions. In
addition, the median follow-up time in
LEADER was 3.8 years (11), and longer-
term neoplasm risk could not be as-
sessed.
Second, neoplasms in some tissue
types may have been subject to detec-
tion bias (e.g., due to gastrointestinal ad-
verse events or weight loss observed
with liraglutide), and a role for detection
or surveillance bias in the relationship
between diabetes and cancer has been
suggested previously (35,36).
Third, a relatively low proportion of
potential neoplasms captured were con-
firmed by adjudication. These events
were reported and sent for adjudication
according to a broad study definition to
help ensure a robust process. The em-
phasis on a histological or cytological
diagnosis during neoplasm adjudication
provided high specificity in confirmed
cases but may also have decreased
sensitivity. To address this, we also ex-
amined cases based on clinical reporting,
which generally confirmed the adjudi-
cated findings.
Fourth, although of scientific and
clinical interest, our subgroup analyses
and sensitivity analyses excluding neo-
plasms occurring ,1 year or ,2 years
after randomization were based on lower
numbers of patients than the main
analyses, further reducing the precision
of the HRs and complicating data inter-
pretation. In addition, LEADER was con-
ducted in a population at high CV risk
and excluded patients based on a history
of malignancy, which could potentially
limit the generalizability of the findings
(37).
Finally, the generalizability of our find-
ings to GLP-1RAs other than liraglutide
up to doses of 1.8 mg daily is unclear.
In conclusion, overall safety analyses
of data from the LEADER trial do not
suggest a major increase in the risk of
malignant neoplasms with liraglutide, in
general terms, versus placebo. Based on
small numbers, imbalances with uncer-
tain significance were observed for neo-
plasms of some tissue types, without
allowing firm conclusions. We cannot
comment on the longer-term neoplasm
risk beyond a median follow-up time of
3.8 years. Only long-term, larger, pro-
spective, pragmatic, or observational
registry studies may help to answer
questions about the longer-term safety
of liraglutide and other GLP-1RAs.
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